LY-266,097

LY-266,097 is a research ligand which acts as a potent and selective antagonist for the 5-HT_2B receptor, with more than 100x selectivity over the related 5-HT_2A and 5-HT_2C receptor subtypes.^[1] It has been used to study the role of the 5-HT_2B receptor in modulating dopamine release in the brain,^[2]^[3] as well as its involvement in other processes such as allodynia.^[4]

LY-266,097
Legal status

Legal status	In general: uncontrolled
Identifiers
IUPAC name 1-[(2-chloro-3,4-dimethoxyphenyl)methyl]-6-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
CAS Number	208591-60-0^Y
PubChem CID	9953185
ChemSpider	8128795
UNII	2Z9TC7YMY4
ChEMBL	ChEMBL95121
Chemical and physical data
Formula	C₂₁H₂₃ClN₂O₂
Molar mass	370.88 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC1=CC2=C(C=C1)NC3=C2CCNC3CC4=C(C(=C(C=C4)OC)OC)Cl
InChI InChI=1S/C21H23ClN2O2/c1-12-4-6-16-15(10-12)14-8-9-23-17(20(14)24-16)11-13-5-7-18(25-2)21(26-3)19(13)22/h4-7,10,17,23-24H,8-9,11H2,1-3H3 Key:NJLHHCITDFZZSE-UHFFFAOYSA-N

References

^ Krempaska K, Barnowski S, Gavini J, Hobi N, Ebener S, Simillion C, et al. (January 2020). "Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls [corrected]". Respiratory Research. 21 (1): 25. doi:10.1186/s12931-020-1275-8. PMC 6964061. PMID 31941499.

^ Auclair AL, Cathala A, Sarrazin F, Depoortère R, Piazza PV, Newman-Tancredi A, Spampinato U (September 2010). "The central serotonin 2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity". Journal of Neurochemistry. 114 (5): 1323–1332. doi:10.1111/j.1471-4159.2010.06848.x. PMID 20534001. S2CID 45607832.

^ Devroye C, Cathala A, Haddjeri N, Rovera R, Vallée M, Drago F, et al. (October 2016). "Differential control of dopamine ascending pathways by serotonin2B receptor antagonists: New opportunities for the treatment of schizophrenia". Neuropharmacology. 109: 59–68. doi:10.1016/j.neuropharm.2016.05.024. PMID 27260325. S2CID 46847094.

^ Pineda-Farias JB, Velázquez-Lagunas I, Barragán-Iglesias P, Cervantes-Durán C, Granados-Soto V (February 2015). "5-HT_2B Receptor Antagonists Reduce Nerve Injury-Induced Tactile Allodynia and Expression of 5-HT_2B Receptors". Drug Development Research. 76 (1): 31–39. doi:10.1002/ddr.21238. PMID 25620128. S2CID 26049138.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Last edited on 3 February 2024,

at 22:18

Languages

This page is not available in other languages.

●This page was last edited on 3

February 2024, at 22:18 (UTC).

●Content is available under CC B

Y-SA 4.0 unless otherwise noted.